Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch OTLKW and buy or sell other stocks, options, and ETFs commission-free!

About OTLKW

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. 

CEO
C. Russell Trenary, III
CEOC. Russell Trenary, III
Employees
Employees
Headquarters
Iselin, New Jersey
HeadquartersIselin, New Jersey
Founded
2010
Founded2010
Employees
Employees

OTLKW Key Statistics

Market cap
Market cap
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
Average volume
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
52 Week high
52 Week low
52 Week low

OTLKW News

Yahoo Finance 7d
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split - Yahoo Finance

Outlook Therapeutics, Inc. ISELIN, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical comp...

Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split - Yahoo Finance
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.